In this 30 minute audio, Danny and I explain what we believe Glycominetics is really about and what management is attempting to do with Upro, the company's lead drug in advanced clinical studies for AML. We discuss why we believe the real story here is hematopoietic stem cell transplantation > "HSCT."
We also discuss what we expect to hear on the company's upcoming earnings call, Wednesday March 29th, 2023. Enjoy the audio!
Scott
